Skip to main content
MLAB
NASDAQ Industrial Applications And Services

Mesa Labs Q2 Operating Income Jumps 78% to $8.4M; Board Authorizes New $40M Buyback

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Scientific Instrument Stocks · Technology
Sentiment info
Positive
Importance info
7
Price
$122
Mkt Cap
$715.264M
52W Low
$69.51
52W High
$144.35
52W Position info
76% above low
Off High info
15% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

MLAB sits 76% above its 52-week low of $69.51.

Summary

Mesa Labs grew Q2 revenue 2.6% to $62.3M while operating income jumped 77.6% to $8.4M, and the board authorized a new $40.0M share repurchase program. Clinical Genomics weakness will trigger a goodwill impairment test in Q3 FY2027.


Key Events · Earnings and Guidance · MLAB

  • Q2 Operating Income Up 78%

    Revenue rose 2.6% to $62.3M and operating income jumped 77.6% to $8.4M; diluted EPS was $0.75 versus $0.45 a year earlier.

  • Six-Month Operating Income Nearly Doubles

    First-half operating income reached $15.4M, up 98.0% from $7.8M, on gross margin of 64.4% versus 61.7%.

  • New $40M Buyback Authorized

    On November 4, 2026 the board terminated the 2005 repurchase program and authorized up to $40.0M of buybacks through December 31, 2028, funded from cash and operations.

  • Debt Paydown Continues

    The revolver fell to $67.3M from $84.5M at March 31, 2026, with $57.8M available; an additional $5.0M was repaid after quarter-end.


Analysis · MLAB · Industrial Applications And Services

Mesa's fiscal Q2 delivered real operating leverage: revenue rose 2.6% to $62.3M while operating income jumped 77.6% to $8.4M and diluted EPS climbed to $0.75 from $0.45, lifting six-month operating income 98.0% to $15.4M. Gross margin improved on lower contract labor and tariff costs, and the company kept paying down debt, cutting the revolver to $67.3M from $84.5M at fiscal year-end. Against that backdrop the board replaced a dormant 2005 repurchase authorization with a new $40.0M program through December 2028, and a September credit amendment now permits buybacks. The offsetting risk is Clinical Genomics: revenue fell 8.8% and management will run a quantitative goodwill and long-lived asset impairment test in Q3 FY2027 on $17.2M of goodwill plus $7.2M of intangibles, so a non-cash charge is possible.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLAB was trading at $122.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $715.3M. The 52-week trading range was $69.51 to $144.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLAB - Latest Insights

MLAB
Nov 09, 2026, 4:40 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $122.00
Real-time Price: $122.00 info
Change: $0 (0%) info
Market Cap: $715.264M info
MLAB
Nov 09, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $122.00
Real-time Price: $122.00 info
Change: $0 (0%) info
Market Cap: $715.264M info
MLAB
Oct 13, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $128.07
Real-time Price: $122.00 info
Change: -$6.07 (-5%) info
Market Cap: $715.264M info
MLAB
Oct 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $128.07
Real-time Price: $122.00 info
Change: -$6.07 (-5%) info
Market Cap: $715.264M info
MLAB
Aug 17, 2026, 11:49 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $108.36
Real-time Price: $122.00 info
Change: +$13.64 (+13%) info
Market Cap: $715.264M info